Voriconazole, a new antifungal agent, is increasingly being used after HSCT. The hepatic cytochrome P450 isoenzyme 2C19 plays a significant role in voriconazole metabolism. As CYP2C19 exhibits significant genetic polymorphism, some patients metabolize voriconazole poorly resulting in increased plasma drug levels. The clinical significance of this is unknown, and the utility of monitoring voriconazole levels is unclear. Steady-state trough plasma voriconazole levels were obtained in 25 allogeneic HSCT recipients using an HPLC assay. Patients had drug levels checked once (n ¼ 13), twice (n ¼ 10), or X3 times (n ¼ 2) 5-18 days (median 10) after starting voriconazole or dose modification. The 41 voriconazole levels were 0.2-6.8 lg/ml (median 1.6); 6 (15%) were o0.5 (possibly below the in vitro MIC 90 for Aspergillus spp.). Voriconazole concentrations correlated with aspartate aminotranferase (AST) (r ¼ 0.5; P ¼ 0.0009) and alkaline phosphatase (r ¼ 0.34; P ¼ 0.03), but not with creatinine, bilirubin and alanine aminotransferase (ALT). Since liver dysfunction is common after HSCT, it was not possible to determine if elevated AST and alkaline phosphatase levels were the cause or the consequence of higher voriconazole levels. We conclude that trough voriconazole levels vary considerably between patients, and suggest monitoring levels in patients receiving voriconazole for confirmed fungal infections, and in those with elevated AST or alkaline phosphatase levels. Bone Marrow Transplantation (2005) 35, 509-513.
Summary:
Voriconazole, a new antifungal agent, is increasingly being used after HSCT. The hepatic cytochrome P450 isoenzyme 2C19 plays a significant role in voriconazole metabolism. As CYP2C19 exhibits significant genetic polymorphism, some patients metabolize voriconazole poorly resulting in increased plasma drug levels. The clinical significance of this is unknown, and the utility of monitoring voriconazole levels is unclear. Steady-state trough plasma voriconazole levels were obtained in 25 allogeneic HSCT recipients using an HPLC assay. Patients had drug levels checked once (n ¼ 13), twice (n ¼ 10), or X3 times (n ¼ 2) 5-18 days (median 10) after starting voriconazole or dose modification. The 41 voriconazole levels were 0.2-6.8 lg/ml (median 1.6); 6 (15%) were o0.5 (possibly below the in vitro MIC 90 for Aspergillus spp.). Voriconazole concentrations correlated with aspartate aminotranferase (AST) (r ¼ 0.5; P ¼ 0.0009) and alkaline phosphatase (r ¼ 0.34; P ¼ 0.03), but not with creatinine, bilirubin and alanine aminotransferase (ALT). Since liver dysfunction is common after HSCT, it was not possible to determine if elevated AST and alkaline phosphatase levels were the cause or the consequence of higher voriconazole levels. We conclude that trough voriconazole levels vary considerably between patients, and suggest monitoring levels in patients receiving voriconazole for confirmed fungal infections, and in those with elevated AST or alkaline phosphatase levels. 1-3 The drug is metabolized in the liver via the cytochrome P450 pathway by the isoenzymes CYP2C19, CYP2C9, and CYP3A4. CYP2C19, the major enzyme responsible for voriconazole metabolism, exhibits genetic polymorphism resulting in reduced drug metabolism in 15-20% patients of Asian descent, and 3-5% of Caucasians and Blacks. Heterozygotes and homozygotes for the polymorphic isoenzyme (poor metabolism) may experience a two-and four-fold increase in drug exposure. 3 An increase in voriconazole levels may result in hepatotoxicity, 3, 4 particularly in HSCT recipients who are already at risk of liver dysfunction. 5 However, routine monitoring of voriconazole levels is not recommended.
Additionally, HSCT recipients often receive drugs that have interactions with voriconazole, such as cyclosporine, tacrolimus, warfarin, benzodiazepines, and calcium channel blocking agents. Levels of these drugs are affected by voriconazole although they do not appear to affect voriconazole levels. 3 No published, peer-reviewed data are available on voriconazole interactions with cytotoxic chemotherapeutic agents, valaciclovir, acyclovir, mycophenolate mofetil, and other drugs that are used in HSCT recipients.
Although some information does exist on voriconazole levels in healthy volunteers and patients, [6] [7] [8] no data are available on plasma voriconazole levels in HSCT recipients. The lack of information in HSCT recipients and concerns about hepatotoxicity in this setting prompted us to monitor voriconazole levels in allogeneic HSCT recipients.
We present a retrospective analysis of our experience with voriconazole therapeutic drug monitoring, which suggests that monitoring voriconazole trough concentrations may be desirable under certain circumstances.
Patients and methods
Records of 25 adult patients with hematologic diseases (eight acute myeloid leukemia, seven non-Hodgkin's lymphoma, three chronic lymphocytic leukemia, three Hodgkin's disease, two myeloma, one acute lymphoblastic leukemia, one aplastic anemia), who underwent submyeloablative allogeneic HSCT from HLA-identical siblings (n ¼ 9) or 9-10/10 allele-matched unrelated donors (n ¼ 16) between November 2002 and November 2003 in whom voriconazole levels were available, were reviewed. The aim was to correlate levels with biochemical parameters, and look at any variability in levels. Studying clinical outcome in terms of either efficacy or toxicity was not an aim.
Transplantation
The conditioning regimen consisted of 100 mg/m 2 melphalan on day À1 as a single agent (n ¼ 7; prior autograft) or with added 50 mg/kg cyclophosphamide on day À2 (n ¼ 18; no prior autograft). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (n ¼ 9; HLA-identical sibling donors) or tacrolimus (n ¼ 16; unrelated donors) in combination with mycophenolate mofetil. All patients were on both immunosuppressive agents when levels were drawn. Cyclosporine and tacrolimus levels were monitored regularly and drug doses adjusted to keep levels within the appropriate range for the time post transplant. All patients were also on prophylactic itraconazole (prior to being switched to voriconazole), prophylactic valaciclovir or therapeutic ganciclovir/valganciclovir, and levofloxacin.
Voriconazole administration
A total of 22 patients were started on voriconazole at the dose of 200 mg twice daily orally either prophylactically, when corticosteroid therapy was started for GVHD, or empirically as for prolonged, unresponsive fever. The dose was subsequently increased to 300 mg twice daily orally in four of these patients. In two patients with suspected aspergillosis, the drug was started at the dose of 400 mg twice daily orally for a day and then switched to 200 mg twice daily. In one patient with confirmed aspergillosis diagnosed several months prior to transplantation, it was started at 300 mg twice daily. No patient received the drug intravenously. The drug was started on day þ 1 to þ 178 (median þ 15) after HSCT.
Voriconazole levels
Steady-state plasma voriconazole trough levels were monitored using a high-performance liquid chromatography (HPLC) assay, 9 5 days to 7 months (median 15 days) after starting the drug or changing the dose. The voriconazole dose was increased if the level was o0.5 mg/ ml and decreased if the level was 47 mg/ml.
Statistical methods
Regression analysis was used to assess correlation between plasma voriconazole trough levels and serum creatinine, bilirubin, alanine aminotransferase (ALT; normal range 0-40 IU/l), aspartate aminotranferase (AST; normal range 0-40 IU/l), and alkaline phosphatase (normal range 0-100 IU/l). Fisher's exact test was used to compare differences between categoric variables. The KruskallWallis test was used to compare differences between continuous variables. This retrospective data analysis was approved by the Institutional Review Board as part of a detailed review of recipients of nonmyeloablative allografts.
Results
A total of 41 voriconazole levels were obtained in 25 patients. Levels were checked once (n ¼ 13), twice (n ¼ 10), thrice (n ¼ 1; third level checked because of the development of liver failure secondary to GVHD), and five times (n ¼ 1; the last three levels checked over a period of 5 months because of the development of chronic renal failure). Table 1 shows summary data on the levels. Figure 1 depicts serial drug levels in the 12 patients who had levels tested more than once. It is interesting to note that the four instances of change in dose from 200 mg twice daily to 300 mg twice daily resulted in plasma level changes of 0.4 Â , 6.4 Â , 6.6 Â , and 7.7 Â .
There was no correlation between voriconazole levels and creatinine (r ¼ 0.09; P ¼ 0.62), bilirubin (r ¼ 0.04; P ¼ 0.82), and ALT (r ¼ 0.25; P ¼ 0.11). There was significant correlation between voriconazole levels and AST ( Figure 2 ) and alkaline phosphatase ( Figure 3 ).
As Table 2 shows, six of 34 levels obtained at the dose of 200 mg twice daily were o0.5 mg/ml compared to zero of seven at 300 mg twice daily (P ¼ 0.54). Of the 34 levels obtained at the dose of 200 mg twice daily, 14 were o1mg/ml compared to one of seven at 300 mg twice daily (P ¼ 0.22). had more than one level tested. The four broken lines represent a transition from 200 mg twice daily to 300 mg twice daily.
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The weight of the patients varied considerably ( Table 2) . As a result, the daily dose per kg body weight was widely variable; 2.7-10.2 mg (median 5.6). The relationship between the dose per kg and level was weak (r ¼ 0.26; P ¼ 0.099). The mg/kg dose on which voriconazole levels were o0.5 mg/ml (2.9-8.9; median 5.1) was not significantly different (P ¼ 0.35) from the dose at which levels were higher (2.7-10.2; median 5.4). Similarly, the mg/kg dose on which voriconazole levels were o1.0 mg/ml (2.7-8.9; median 6.1) was not significantly different (P ¼ 0.19) from the dose at which levels were higher (3.4-10.2; median 5.5).
The main concomitant medications included immunosuppressive agents and antimicrobials. Other concomitant medications included ursodiol, analgesics, antihypertensives, and occasionally, antidepressants. Most importantly, none of the patients was on rifampin, rifabutin, carbamazepine, long-acting barbiturates, or phenytoin -agents known to reduce voriconazole levels by CYP450 induction. Similarly, none of the patients was receiving efavirenz, ritonavir, other protease inhibitors, nonnucleoside reverse transcriptase inhibitors, cimetidine, ranitidine, or macrolide antibiotics -agents which may increase drug levels.
Discussion
To the best of our knowledge, this is the only report of plasma voriconazole levels in allogeneic HSCT recipients. The most important shortcoming of this exercise is that the clinical implications of the data obtained by us are currently unknown -not only in HSCT recipients, but in all patients. More work, particularly with reference to clinical outcome, will be needed to define this. Why then are the data presented here relevant? We believe they highlight some areas of concern that suggest the need for larger systematic studies in this population of patients to investigate the possibility that voriconazole use does require plasma drug level monitoring. Indeed, a recent report from the Manchester group showed that three of 16 patients in whom drug levels were measured had toxicity in the setting of high levels. 10 Voriconazole is thought to be as easy and convenient to use as fluconazole, but our data suggest that the process may be different and may require closer attention.
As Table 2 and Figure 1 show, there is a great deal of interpatient variability in the levels achieved. Whether this is the result of variable absorption in the setting of mucosal damage and microbial flora change in the gut post transplant, variable metabolism due to genetic polymorphisms, or drug interactions is unknown. Most likely, it stems from a combination of various factors. Additionally, a modest change in the dose (50% increase) can increase the levels several-fold (Figure 1 ). This is expected, based upon the known nonlinear pharmacokinetics of the drug. However, the level may rise significantly without a change in the dose as was seen in two patients (two of the solid lines in Figure 1 ).
As Figures 2 and 3 demonstrate, AST and alkaline phosphatase levels correlate with plasma voriconazole levels. It is unclear if abnormal liver function contributes to accumulation of the drug or higher levels result in hepatotoxicity -or both. However, since liver dysfunction secondary to regimen-related toxicity, drugs, infections, and GVHD is common after HSCT, it is important to clarify the role of voriconazole in this setting.
The variability in the time to checking levels reflects the fact that this was not a prospective study. In two patients, drug levels were obtained a day too early -at 5 days instead of the 6 required to reach a steady state. However, these two levels were 1 and 3.4 mg/ml, respectively, and were within the 'acceptable' range.
Some of the trough levels obtained on recommended dosing of the drug were below 0.5 mg/ml (Tables 1 and 2 ). Low trough levels of the drug would result in lower AUC. Adequate AUC is correlated with efficacy of voriconazole therapy in a murine candidiasis model. 11 While the relationship between MIC 90 , plasma drug levels and clinical outcome is unknown, and appropriate National Committee for Clinical Laboratory Standards (NCCLS) breakpoints remain to be determined, 12 it would appear desirable to have trough drug levels that are higher than 0.5. Since we could not show any obvious relationship between absolute or mg/kg doses and levels, additional work is required to address this issue. Plasma voriconazole levels after HSCT S Trifilio et al
Our survey of infection prophylaxis practices after HSCT, performed in January 2003, 13 showed no voriconazole use because the drug had just become available then. However, voriconazole prophylaxis is increasingly being adopted because of its activity against aspergillosis as well as perceived simplicity of use. However, with widespread use, there is evidence that zygomycosis is emerging as a problem 14 -and it will be important to ensure appropriate monitoring to reduce emergence of aspergillus resistance. However, a limitation of the present study is that clinical outcomes were not examined because of the limited nature of the data.
Based on our findings, we conclude that further work is required to determine the utility of voriconazole therapeutic drug monitoring. Clinical utility of voriconazole level monitoring is unclear in patients receiving the drug prophylactically, those with a low likelihood of a fungal infection, and those with normal liver enzymes.
Therapeutic drug monitoring may be warranted in patients with suspected or proven fungal infections, and in those with abnormal liver function. Table 2 Relationship between absolute dose, weight-adjusted dose, time to drug level measurement, and drug levels 
